Feedback / Questions
Vynfinit (vintafolide) - Novartis
Merck: ASCO 2013
(Merck (MSD) Press Release)
-
Jun 6, 2013 -
Anticipated regulatory submission in US based on P3 PROCEED trial for platinum-resistant ovarian cancer in 2015
Anticipated FDA event
•
Ovarian Cancer
http://www.merck.com/investors/events-and-presentations/home.html
Jun 6, 2013
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.